GlassScriptPhysician profile
Lauren Schulz
NPI 1912134727
$6,380.46
in general payments reported to CMS, 2019-2025
39 companies · $572 in 2025
The $572 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $837 · 2021: $1,462 · 2022: $1,028 · 2023: $814 · 2024: $938 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.70 |
| Education | $153.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $999.94 | 2019-2024 | Myrbetriq, Xtandi |
| Teleflex LLC | $462.23 | 2021-2023 | Urolift |
| Axonics, INC. | $446.06 | 2023-2024 | Bulkamid, Axonics |
| Endo Pharmaceuticals INC. | $442.70 | 2019-2023 | Edex, Xiaflex, Aveed |
| Pfizer INC. | $340.55 | 2019-2025 | |
| Caldera Medical, INC | $323.99 | 2020-2022 | |
| Abbvie INC. | $322.05 | 2022-2024 | Botox |
| Antares Pharma, INC. | $317.20 | 2020-2025 | Xyosted |
| Janssen Biotech, INC. | $289.93 | 2019-2025 | Erleada |
| Boston Scientific Corporation | $241.47 | 2019-2021 | |
| Urovant Sciences INC | $220.34 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $204.28 | 2019-2020 | |
| Coloplast Corp | $193.62 | 2019-2023 | Speedicath |
| Medtronic, INC. | $191.33 | 2021-2025 | Interstim |
| Endo USA, INC. | $187.79 | 2024-2025 | Xiaflex, Aveed, Edex |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $160.50 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $105.63 | 2021-2023 | Prolaris |
| Dentsply Ih Ab | $102.49 | 2023-2025 | Lofric, Lofric |
| Medtronic USA, INC. | $96.92 | 2019-2020 | |
| Tolmar, INC. | $87.77 | 2023-2024 | |
| Acerus Pharmaceuticals Corporation | $85.96 | 2021-2022 | |
| Dentsply Ih INC. | $71.63 | 2021-2022 | |
| Halozyme INC | $50.98 | 2023 | |
| 180 Medical, INC. | $48.96 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $47.36 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $46.22 | 2021-2022 | |
| Millicent US INC | $44.10 | 2019-2021 | |
| Mission Pharmacal Company | $35.05 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.93 | 2021-2024 | Lynparza |
| Urogen Pharma, INC. | $25.62 | 2023 | Jelmyto |
| Accord Healthcare, INC. | $21.75 | 2022 | |
| Sumitomo Pharma America, INC. | $21.53 | 2025 | Gemtesa |
| Clarus Therapeutics INC. | $19.54 | 2021 | |
| Eisai INC. | $18.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.65 | 2021 | |
| Olympus America INC. | $16.45 | 2025 | Itind System |
| Hollister Incorporated | $13.92 | 2024 | Infyna Chic, Vapro Plus Pocket, Vapro |
| Abc Home Medical Supply, INC. | $13.92 | 2024 | |
| Allergan, INC. | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Schulz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.